Niclosamide Therapy in Diabetic Kidney Disease

This study was an open-labeled randomized controlled parallel clinical study designed to investigate the role of niclosamide in DKD. Eligible patients were randomly assigned to the niclosamide arm or the control arm. Randomization was carried out based on the days of the hospital visit every week. Patients in the niclosamide arm received ramipril plus niclosamide 1 g once daily, and patients in the control arm received ramipril only for 6 months. Ramipril was chosen as it is routinely used as standard therapy for diabetic patients with albuminuria in Internal Medicine Department, Tanta University Hospital, Tanta, Egypt.

Free full text: Click here

El-fatatry B.M., El-Haggar S.M., Ibrahim O.M, & Shalaby K.H. (2023). Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial. Diabetology & Metabolic Syndrome, 15, 22.

Publication 2023

Niclosamide Patients Ramipril

Corresponding Organization : Tanta University

Top 5 similar protocols

Variable analysis

independent variables

Niclosamide

dependent variables

Role of niclosamide in DKD

control variables

Ramipril

controls

Positive control: Patients in the control arm received ramipril only.
Negative control: Not explicitly mentioned.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!